References
- Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am J Med Sci 1997;314:245–9
- Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551–81
- Foxman B. Recurring urinary tract infections: incidence and risk factors. Am J Public Health 1990;80:331–3
- Baerheim A, Digranes A, Jureen R, Malterud K. Generalized symptoms in adult women with acute uncomplicated lower urinary tract infection: An observational study. Medscape Gen Med 2003;5:1–10
- Foxman B, Frerichs RR. Epidemiology of urinary tract infections. I. Diaphragm use and sexual intercourse. Am J Public Health 1985;75:1308–13
- Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135:9–16
- Tucker MK, Brigio FD, Sirotenko GA, et al. A ‘gap’ between physician and patient assessment of symptom severity in acute cystitis? Postgrad Med Special Report 2004. p. 11–20
- Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003;49:53–70
- Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial therapy of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745–58
- Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections [Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)]. Eur Urol 2001;40:576–88
- Gupta K, Stamm WE. Outcomes associated with trimetho prim/ sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents 2002;19: 554–6
- Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resist ance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001;33:89–94
- Karlowsky JA, Kelly LJ, Thornsberry C, et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540–5
- Karlowsky JA, Thornsberry C, Jones ME, et al. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoro quinolones and nitrofurantoin. Clin Infect Dis 2003;36: 183–7
- Henry DC, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24:2088–104
- Bayer Pharmaceuticals Corporation. CIPRO→ XR (ciprofloxacin extended-release tablets). US Prescribing information, 2004. Available online: www.univgraph.com/bayer/inserts/ciproxr.pdf [accessed 5 May 2005]
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard. NCCLS document M7-A6. Villanova (PA): NCCLS; 2003
- Wild DJ, Clayson DJ, Keating K, Gondek K. Validation of a patient-administered questionnaire to measure activity impairment as a result of uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA) [abstract PUK18. Presented at the ISPOR 7th Annual European Congress. 24–26 October, 2004, Hamburg, Germany]. Value Health 2004;7: 803
- Clayson DJ, Wild DJ, Keating K, Gondek K. Validation of a patient-administered questionnaire to measure the severity of lower urinary tract symptoms in uncomplicated urinary tract infection: the UTI Symptom Assessment (USA) questionnaire. Br J Urol 2005; in press [Accepted Dec 2004]
- Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? The case of the King’s Health Questionnaire and overactive bladder. Br J Obstet Gyencol 2004;111:605–12
- Colgan R, Keating K, Dougouih M. Survey of symptom burden in women with uncomplicated urinary tract infections. Clin Drug Invest 2004;24:55–60